Immunic, Inc. (IMUX)
Nasdaq · Healthcare · Biotechnology
$8.07+1.38%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $110M
- 52-week range
- $5.06 – $17.43
- 52-week change
- −9.55%
- EPS (trailing)
- −$3.83
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$97.2M
- Diluted EPS
- −$0.62
- Free cash flow
- −$86.0M
From the company’s annual report on SEC EDGAR.
About Immunic, Inc.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Headquarters: New York, United States · 100 employees · imux.com